Subscriber Only
Politics
Trump Targets Drug Middlemen With ‘Devastating’ Rebate Plan
By and
Updated on
-
Proposal is part of long-awaited rules targeting drug costs
-
Shares fall at CVS and Cigna, which run major drug plans
The Trump administration proposed ending a complex system of drug rebates that influence tens of billions of dollars in U.S. pharmaceutical spending, a move that could upend the relationship between drugmakers and pharmacy benefits middlemen.
The proposal, a long-awaited part of the administration’s plan to target high list prices of drugs, would ban rebates paid by drugmakers to pharmacy benefit managers, or PBMs, in government programs like Medicare.
